A group of over 40 healthcare, consumer and addiction-treatment advocates has sent a letter to the FDA urging the agency to withdraw its authorization of Zogenix's (ZGNX -1.8%) Zohydro opioid painkiller.
The latest move comes after 29 state attorneys general sent a similar letter to the FDA in December, while in November, members of Congress asked the agency to review the approval.
The fear is the potential for abuse that the narcotic pill presents, especially because of its high potency.
"It will kill people as soon as it's released," says Andrew Kolodny of Physicians for Responsible Opioid Prescribing.
Zohydro is set to become available in March.